VRX Silica【VRX】銘柄情報

VRX Silica Limited (VRX) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.035

( -5.41% )

買値

0.035

売値

0.038

出来高

1,591,682

0.035 日の範囲 0.038

0.035 52 週間の範囲 0.17

時価総額

27.266M

前日終値

0.037

始値

0.0375

時刻

59267

0.035

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

AUD 472,354

発行済株式数

779,024,935

配当利回り

PER

-8.59

1 株当たり利益 (EPS)

-0

歳入

129.95k

純利益

-3.42M

VRX Silica Limited, together with its subsidiaries, engages in the exploration and development of mineral properties in Australia. The company explores for silica. It owns 100% interests in the Arrowsmith and the Muchea silica sand projects located to the north of Perth in Western Australia; and the... VRX Silica Limited, together with its subsidiaries, engages in the exploration and development of mineral properties in Australia. The company explores for silica. It owns 100% interests in the Arrowsmith and the Muchea silica sand projects located to the north of Perth in Western Australia; and the Boyatup silica sand project located to the east of the port town of Esperance. The company was formerly known as Ventnor Resources Limited and changed its name to VRX Silica Limited in December 2018. VRX Silica Limited was incorporated in 2010 and is headquartered in West Perth, Australia. 詳細を表示

セクター

Materials

業界

Mining

ウェブサイト

vrxsilica.com.au

本社

West Perth, Australia

設立

2026

VRX Silica Limited is listed in the Materials sector of the オーストラリア証券取引所 with ticker VRX. The last closing price for VRX Silica was AUD0.04. Over the last year, VRX Silica shares have traded in a share price range of AUD 0.035 to AUD 0.17.

VRX Silica currently has 779,024,935 shares in issue. The market capitalisation of VRX Silica is AUD27.27 million. VRX Silica has a price to earnings ratio (PE ratio) of -8.59.

Valeant Pharmaceuticals to Announce 2009 Fourth Quarter and Year Results on February 22, 2010

ALISO VIEJO, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it will host a...

FDA Accepts NDA Filing for Retigabine

MAA successfully validated by EMEA ALISO VIEJO, Calif., Dec. 30 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE:VRX) today...

Critical Alerts for AIG, Baidu.com, PPG, Jefferies Group, and Valeant Pharmaceuticals Released by Seven Summits Research

CHICAGO, Nov. 24 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for AIG, BIDU, PPG, JEF, and VRX. Seven Summits Strategic...

Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American Association for the Study of

ALISO VIEJO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals (NYSE:VRX) today announced that results from the week-72 analysis...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.003	-7.89473684211	0.038	0.044	0.035	874774	0.03972184	DE
4	-0.01	-22.2222222222	0.045	0.047	0.035	613980	0.04059043	DE
12	-0.019	-35.1851851852	0.054	0.061	0.035	483722	0.04697934	DE
26	-0.038	-52.0547945205	0.073	0.078	0.035	473538	0.05583799	DE
52	-0.04	-53.3333333333	0.075	0.17	0.035	525709	0.08120772	DE
156	-0.1	-74.0740740741	0.135	0.18	0.026	472523	0.06901841	DE
260	-0.2	-85.1063829787	0.235	0.28	0.026	440669	0.10664409	DE